Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acvd.2018.04.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biodegradable Stents in the Treatment of Arterial Stenosis.
J Clin Med
January 2025
Department of Accident and Emergency, Etlik City Hospital, Ankara 06170, Turkey.
Arterial diseases (ADs) are a significant health problem, with high mortality and morbidity rates. Endovascular interventions, such as balloon angioplasty (BA), bare-metal stents (BMSs), drug-eluting stents (DESs) and drug-coated balloons (DCBs), have made significant progress in their treatments. However, the issue has not been fully resolved, with restenosis remaining a major concern.
View Article and Find Full Text PDFMagnetic resonance angiography in diagnostic long-term follow-up of primary patency of the MOTIV drug-eluting bioresorbable vascular scaffold in the region below the knee: 5 years of experience.
PLoS One
January 2025
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Purpose: Treatment of peripheral artery disease (PAD) in the region below the knee (BTK) is dissatisfying as failure of treated target lesions (TLF) is frequent and diagnostic imaging is often challenging. In the BTK-region metallic drug-eluting stents (mDES) yielded best results concerning primary patency (PP), but also annihilate signal in magnetic resonance angiography (MR-A). A recently introduced non-metallic drug eluting bioresorbable Tyrocore® vascular scaffold (deBVS), that offers an option for re-treatment of lesions due to its full degradation within 3-4 years after placement, was investigated with respect to its compatibility with MR-A to unimpededly depict previously treated target lesions.
View Article and Find Full Text PDFHow Can We Optimize the Results of Coronary Bioresorbable Scaffolds?
Circ Cardiovasc Interv
January 2025
Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain.
Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis: The OPTIMIS Trial.
Circ Cardiovasc Interv
January 2025
Department of Cardiology, Odense University Hospital, Denmark (K.N.H., J.T., M.N., M.H., J.E.-G., K.T.V., A.J., H.S.H., J.F.L., L.O.J.).
Background: Bioresorbable scaffolds (BRS) were developed to overcome limitations related to late stent failures of drug-eluting stents, but lumen reductions over time after implantation of BRS have been reported. This study aimed to investigate if lesion preparation with a scoring balloon compared with a standard noncompliant balloon minimizes lumen reduction after implantation of a Magmaris BRS assessed with optical coherence tomography and intravascular ultrasound.
Methods: Eighty-two patients with stable angina were randomized in a ratio of 1:1 to lesion preparation with a scoring balloon versus a standard noncompliant balloon before implantation of a Magmaris BRS.
Bioresorbable Vascular Scaffolds Journey: A New Brick Into a Still Dismantled Wall.
JACC Cardiovasc Interv
January 2025
Hospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!